Liptruzet (Atorvastatin Calcium, Ezetimibe)

Liptruzet is prescribed to treat lipid disorders by targeting cholesterol synthesis and absorption pathways.

• Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol and total cholesterol levels.
• Mixed dyslipidemia: reduces LDL cholesterol while modestly improving triglycerides and high‑density lipoprotein (HDL).
• Primary hyperlipidemia: provides combined inhibition of hepatic cholesterol production and intestinal absorption to achieve target lipid goals.

• Atorvastatin Calcium competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL. Ezetimibe blocks the NPC1L1 transporter on enterocytes, reducing dietary and biliary cholesterol absorption. The dual action results in a synergistic reduction of plasma LDL‑C and total cholesterol.

Adverse reactions may occur with Liptruzet and should be monitored.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Myalgia: muscle aches without weakness.
• Abdominal pain: discomfort in the upper abdomen.
• Diarrhea: loose stools occurring intermittently.
• Nausea: feeling of queasiness, may resolve with continued therapy.
• Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Acute liver injury: marked elevation of hepatic transaminases.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Myopathy: muscle weakness with elevated CK.
• Pancreatitis: abdominal pain with elevated pancreatic enzymes.
• Interstitial lung disease: unexplained respiratory symptoms.

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters.

• Liver function monitoring: obtain baseline ALT/AST and repeat periodically.
• Muscle symptom assessment: evaluate for unexplained muscle pain or weakness.
• Drug interaction review: check for concomitant CYP3A4 inhibitors or other lipid‑lowering agents.
• Contraindication in active liver disease: avoid use in patients with ongoing hepatic impairment.
• Renal impairment caution: dose adjustment may be required in severe renal dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Liptruzet may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure.
• Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis.
• Cyclosporine: elevates both atorvastatin and ezetimibe concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Digoxin: potential increase in serum levels.
• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.
• Fibrates (e.g., fenofibrate): monitor for additive muscle toxicity.
• Grapefruit juice: modestly raises atorvastatin levels.